B+
Bull case
25%
Probability
Target price
$25.00
Analysis reference price unavailable
Analysis 2026-09-26 · RankAlpha Sentiment Codex
TNDM
Tandem Diabetes CareFNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$18.00
Analysis reference price unavailable
Analysis 2026-09-26 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$10.00
Analysis reference price unavailable
Analysis 2026-09-26 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-26
Recent news sentiment (30D)
-26.0
Negative
Company
-
Unavailable
Macro
-26.0
Negative
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+59.5
Score
AI commentary
The $15.72 September 25 anchor is about 6.8% below the prior baseline's $16.87 price, despite constructive Q2 operating evidence. The packet does not establish the cause of the intervening decline. One target cut is confirmed, but comprehensive post-print estimate revisions and a reliable explanation of the price reaction are unavailable. The positive deterministic prior supports an upside-skewed watchlist view, not a high-conviction upgrade. Sentiment metric zeros denote unavailable measurements, not neutral readings. The August Form 4 disposition was tax withholding, not evidence of discretionary selling or operating weakness. [#SEC-FORM4-2026-08-18]
RankAlpha Sentiment Codex - 2026-09-26
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-11-30catalystU.S. pump and pharmacy-channel tractionHigh impact
Q2 U.S. pump shipments exceeded 22,000 versus approximately 21,000 a year earlier, while the pay-as-you-go model accounted for 10% of U.S. sales. Subsequent shipment and channel-mix disclosures will test whether adoption accelerates without eroding margins. The date is an estimated review window. [#SEC-8K-2026-08-06]
2026-12-31eventMobi tubeless regulatory decision and launchHigh impact
Tandem reported submitting a 510(k) for Mobi tubeless capability in Q2. Clearance and commercialization could broaden its pump offering; the decision date and launch timing remain uncertain. The date shown is a monitoring window, not an announced deadline. [#SEC-8K-2026-08-06] [#8-K-2026-08-06]
2027-06-30catalystInternational expansion and sustained operating leverageHigh impact
Q2 international pump shipments were approximately 11,000 versus 9,000 a year earlier, Tandem began the international Mobi rollout, and gross margin reached 57%. Sustained growth and margin gains would strengthen the profitability case, but one quarter does not establish a durable trend. [#SEC-8K-2026-08-06]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-26 • Updated nightlySource: Internal modelMethodology